Treatment Goals in Psoriatic Arthritis

NCT03620188 | Completed

• 1 other identifier: IRB00184580
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

The PaGoPsA study objective is to ascertain if guideline-based psoriatic arthritis clinical care achieves individual patient goals as articulated by patients, and to identify predictors of achieving individual patient goals from psoriatic arthritis treatment.

Conditions

Psoriatic Arthritis

Keywords

Patient treatment goals

Outcome Measures

Primary Outcomes (1)

• Predictors of reaching PsA treatment goals/treatment success from a patient perspective.

  The primary outcome determination is based on the patients' report of whether they are/are not at goal with their PsA treatment.

  12-16 weeks

Secondary Outcomes (5)

• To define a status of PsA treatment where patient treatment goals have been met.

  52 weeks

• Improvement thresholds (treatment success) that correspond to a patient transition from goals not met to met.

  12-16 weeks

• Worsening thresholds (treatment failure) if transition is from goals met to not met.

  12-16 weeks

• Prevalence of treatment success in guideline -based treatment in psoriatic arthritis from the patients' perspective

  52 weeks

• Stability of a state of treatment goals met at subsequent study visits.

  52 weeks

Interventions

Standard of care OTHER

Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.

Eligibility Criteria

• Age: 18 Years - 95 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with a diagnosis of psoriatic arthritis meeting CASPAR classification criteria for psoriatic arthritis who are followed every 3-4 months for regular rheumatologic care. Consecutive clinic patients will be recruited.

You may qualify if:

• English speaking/reading adults
• Patients of the Johns Hopkins Arthritis Center and/or the Johns Hopkins Psoriatic Arthritis Clinical Program
• Followed every 3-4 months for regular psoriatic arthritis clinical care
• Meet Classification Criteria for Psoriatic Arthritis (CASPAR)
• Able to interact with touch screen computer.

You may not qualify if:

• None

Sponsors & Collaborators

• Johns Hopkins University: lead
• Amgen: collaborator

Study Sites (1)

Johns Hopkins Bayview

Baltimore, Maryland, 21224, United States

Location

Related Publications (1)

• Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.

  PMID: 27613807 BACKGROUND

Related Links

• Prior work on patient priorities for psoriatic arthritis treatment

MeSH Terms

Conditions

Arthritis, Psoriatic

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Ana-Maria Orbai, MD, MHS

  Johns Hopkins University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 3, 2018
• First Posted: August 8, 2018
• Study Start: December 20, 2018
• Primary Completion: June 30, 2022
• Study Completion: June 30, 2022
• Last Updated: September 21, 2023

Record last verified: 2023-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)